Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Sung Gwe Ahn, MD, PhD
Advertisement
Articles by Sung Gwe Ahn, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice
2
Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era
3
CRT Does Not Improve RFS/OS, Confers High-Grade Toxicity in Cervical Cancer
4
ctDNA Status May Determine Adjuvant Immunotherapy Benefit in MIBC
5
